期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

异基因骨髓移植治疗恶性血液病19例长期疗效分析 被引量：1

暂未订购
导出
摘要 目的:总结分析异基因骨髓移植治疗恶性血液病的长期疗效及相关影响因素。方法:采用HLA全相合同胞间异基因骨髓移植治疗19例恶性血液病患者,移植后采用环孢素A联合短程甲氨蝶呤预防移植物抗宿主病(GVHD)。总结分析其临床资料,统计方法采用寿命表法生存分析。结果:19例均获得造血功能重建。随访时间2～97个月,尚有14例患者健康存活,预期术后5年生存率为73%。结论:异基因骨髓移植是目前治愈恶性血液病的有效方法。移植后疾病复发及GVHD仍是影响长期存活的重要因素。
作者 薛连国 赵利东 王莹 蔡志梅 贾韬 毛建平 陈泽 刘惠杰
机构地区 江苏省连云港市第一人民医院血液科
出处 《实用医学杂志》 CAS 北大核心 2013年第5期799-800,共2页 The Journal of Practical Medicine
关键词 骨髓移植 异基因 恶性血液病 疗效
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献5

二级参考文献10

  • 1Pasquini M. Report on state of the art in blood and marrow transplantation-CIBMTR summary slides Part I 2005 [J].CIBMTR Newsletter, 2006,12 ( 1 ) : 5-8.
  • 2BekassyA N, Hermans J , Gorin N C, et al. Granulocytic sarcoma after allogeneic bone marrow transplantation: a ret2 rospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation[J]. Bone Marrow Transplant, 1996,17(5) :801-808.
  • 3Lee J H, Choi S J. Anti-leukemic effect of graftversus-host disease on bone marrow and extramedullary relapses in acute leukemia [J]. Haematologica, 2005,90(10) : 1380-1388.
  • 4Lee K H, Lee J H, Choi S J, et al. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietie cell transplantation: risk factors and clinical course [ J ]. Bone Marrow Transplant, 2003,32 (8) : 835-842.
  • 5Hertenstein B, Hambach L, Baeigalupo A, et al. Development of leukemia in donor cells after allogeneic stem cell transplantation-a survey of the European Group for Blood and Marrow Transplantation (EBMT) [J]. Haematologiea,2005,90 (7) :969-975.
  • 6Moorman A V,Harrison C J,Buck G A,et al.Karyotype is an independent prognostic factor in adult acute lymphoblasticleukemia(ALL):analysis of cytogenetic data from patientstreated on the Medical Research Council(MRC)UKALLXII/Eastern Cooperative Oncology Group(ECOG)2993trial[J].Blood,2007,109(8):3189-3197.
  • 7Goldstone A H,Richards S M,Lazarus H M,et al.In adults with standard-risk acute lymphoblastic leukemia,the greatestbenefit is achieved from a matched sibling allogeneictransplantation in first complete remission,and an autologoustransplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients:final results of theInternational ALL Trial(MRC UKALL XII/ECOG E2993)[J].Blood,2008,111(4):1827-1833.
  • 8Cornelissen J J,van der Holt B,Verhoef G E,et al.Myeloablative allogeneic versus autologous stem celltransplantation in adult patients with acute lymphoblasticleukemia in first remission:a prospective sibling donor versusno-donor comparison[J].Blood,2009,113(6):1375-1382.
  • 9Thomas X,Boiron J M,Huguet F,et al.Outcome of treatmentin adults with acute lymphoblastic leukemia:analysis of theLALA-94trial[J].J Clin Oncol,2004,22(20):4075-4086.
  • 10Ribera J M,Oriol A,Bethencourt C,et al.Comparison ofintensive chemotherapy,allogeneic or autologous stem celltransplantation as post-remission treatment for adult patientswith high-risk acute lymphoblastic leukemia.Results of thePETHEMA ALL-93trial[J].Haematologica,2005,90(10):1346-1356.

共引文献7

同被引文献3

引证文献1

二级引证文献2

实用医学杂志
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部